Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis.

British journal of cancer - 1 Sept 2018

Krisp Christoph, Parker Robert, Pascovici Dana, Hayward Nicholas K, Wilmott James S, Thompson John F, Mann Graham J, Long Georgina V, Scolyer Richard A, Molloy Mark P

Abstract excerpt

BACKGROUND: Genotyping of melanomas is used to identify patients for treatment with BRAF and MEK inhibitors, but clinical responses are highly variable. This study investigated the utility of protein expression phenotyping to provide an integrated assessment of gene expression programs in BRAF/NRAS melanoma which would be useful for prognosis and may predict response to MEK inhibition. METHODS: Mass spectrometry...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Chromatography, Liquid

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to GTP Phosphohydrolases

Share to Intercellular Adhesion Molecule-1

Share to Melanoma, Cutaneous Malignant

Share to Proteomics

Share to Survival Analysis

Share to Tandem Mass Spectrometry

Source

Open in PubMed Open full text

Identifiers

PMID: 30116025
DOI: 10.1038/s41416-018-0227-2
PMCID: PMC6173697

Genes

BRAF
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis.PMID 30116025Read ↗

Comprehensive Expression Profiling of Tumor Cell Lines Identifies Molecular Signatures of Melanoma ProgressionSemantic proximity Read ↗

Plasma proteome alterations by MAPK inhibitors in BRAFV600-mutated metastatic cutaneous melanoma.Semantic proximity Read ↗

The Hidden Story on Heterogeneous B-raf V600E Mutation Quantitative Protein Expression in Metastatic Melanoma – Association with Clinical Outcome and Tumor PhenotypesSemantic proximity Read ↗

Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapySemantic proximity Read ↗

Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature.Semantic proximity Read ↗

A Gene Expression Signature of Invasive Potential in Metastatic Melanoma CellsSemantic proximity Read ↗

Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanomaSemantic proximity Read ↗

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAF V600-mutated Metastatic MelanomaSemantic proximity Read ↗

The gene expression signatures of melanoma progression.Semantic proximity Read ↗

Differential Gene Expression Common to Acquired and Intrinsic Resistance to BRAF Inhibitor Revealed by RNA-Seq AnalysisSemantic proximity Read ↗

Differential gene expression profiling of primary cutaneous melanoma and sentinel lymph node metastases.Semantic proximity Read ↗

Deep Proteomic Analysis on Biobanked Paraffine-Archived Melanoma with Prognostic/Predictive Biomarker Read-OutSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.